European Clinics in Obstetrics and Gynaecology

, Volume 1, Issue 2, pp 102–114

Endocrine management of breast cancer—biology and current practice

Original Paper

Abstract

Breast cancer frequency is related to age. There are impressive advances in the diagnostic armament and surgical techniques of breast cancer, and yet, it has continued its deadly impact. In women with operable breast cancer, the histologic status of the axillary lymphnodes remains the most useful prognostic information. Today, breast cancer is viewed as a systemic disease with spreads to local and distant sites at the same time. There is a high rate of occult disease. Factors of major influence on breast cancer include reproductive experience, ovarian activity, benign breast disease, familial tendency, genetic differences, dietary considerations and specific endocrine factors. Tamoxifen still is the standard endocrine treatment for hormone-receptor-positive breast cancer both in the adjuvant and metastatic settings. Because of its weak oestrogenicity, tamoxifen may not be optimally effective and can increase the risk of endometrial cancer and stroke. Patients may also be refractory or become resistant to tamoxifen treatment. Aromatase inhibitors block the synthesis of oestrogen, have low intrinsic oestrogenic activity and, thereby, offer the potential of being more effective than tamoxifen. The challenge of the coming years is to identify women who are best treated with an aromatase inhibitor upfront rather than a tamoxifen-to-aromatase inhibitor sequence. Third-generation aromatase inhibitors offer greater benefits in oestrogen receptor (ER)-positive, progesterone-negative and HER-2 overexpressing tumours. Overall, no more than 2–3% of breast cancer occurrences can be attributed to the inherited mutation of either maternal or paternal origin. Autocrine and paracrine regulation of local oestrogen biosynthesis in normal and tumour breast tissue is via growth factors acting upon aromatase activity, which is preferably expressed in the tumour-bearing quadrant. Aromatase regulation operates against a concentration gradient of oestrogens, comparing peripheral plasma to local tissue levels in both premenopausal and postmenopausal women. Clinical observations suggest to routinely determine both ER subtypes and its variants, by which, the prediction of the response of the breast tumours to endocrine therapy may improve. Polymorphisms of cytochrome CYP-17, CYP-1A1 and COMT are found to be associated with an increased risk of breast cancer. To identify high-risk genotypes in women may delineate the individual at increased risk of breast cancer. Arguments in favour of an impact of postmenopausal oestrogen–progestin therapy on pre-existing tumours derive from observations in epidemiologic studies showing no increase in non-invasive breast cancer with hormone therapy; on the other hand, several studies point to a lower grade and earlier stage of disease in hormone users, with subsequently better survival rates. The older a postmenopausal woman, the greater her risk of developing an increase in breast density with hormone therapy. This is considered a good reason to recommend discontinuation of hormone therapy for at least 2 weeks prior to mammography in women older than age 65 who have dense breasts. As yet, there is no endocrine or biological evidence as to a sequential use of non-cross-resistant endocrine therapies. After progression on adjuvant and first-line tamoxifen, ovarian ablation is an appropriate second-line therapy. For premenopausal women with ovarian ablation, the use of a third-line therapy with an aromatase inhibitor appears feasible. In postmenopausal women, a wide choice of endocrine treatment options is available and an optimal sequence has yet to be determined. The widening range of adjuvant endocrine options represents an opportunity to prolong patient benefits in the treatment of hormone-receptor-positive breast cancer. Further refinement is currently investigated. For example, tamoxifen therapy followed by an aromatase inhibitor may lead to a reduction in endometrial pathologies associated with tamoxifen. New adjuvant treatments with chemotherapy or endocrine agents is being used increasingly to down-stage locally advanced and large operable breast cancers, which often become fully resectable; in addition, initially operable tumours requiring mastectomy may be successfully removed by breast-conserving surgery. Patient selection is important to optimise new adjuvant endocrine therapy; only patients with oestrogen-receptor-rich breast cancer are candidates, and postmenopausal women are likely to benefit the most.

Keywords

Reproductive experience Endocrinology Clinical management New developments Future perspectives 

References

  1. 1.
    Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2:104–107Google Scholar
  2. 2.
    Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA (1997) Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82:4258–4265Google Scholar
  3. 3.
    Shyamala G (1997) Roles of estrogen and progesterone in normal mammary gland development. Insights from progesterone receptor null mutant mice and in situ localization of receptor. Trends Endocrinol Metab 8:34–39Google Scholar
  4. 4.
    Klineberg DL, Niemann W, Flamm E, Cooper P, Babitsky G, Valensi Q (1985) Primate mammary development. J Clin Invest 75:1943–1950Google Scholar
  5. 5.
    American Cancer Society (2003) Cancer facts and figures 2003. Available at http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf
  6. 6.
    Loibl S, von Minckwitz G, Kaufmann M (2003) Neues zur Therapie des Mammakarzinoms und der gynäkologischen Karzinome. Zentralbl Gynakol 125:327–330Google Scholar
  7. 7.
    American Cancer Society (2003) Breast cancer facts and figures 2003–2004. Available at http://www.cancer.org/downloads/STT/Caff2003BrFPWSecured.pdf
  8. 8.
    Harris JR, Lippman ME, Veronesi U, Willett W (1992) Breast cancer, part 1. N Engl J Med 327:319–328Google Scholar
  9. 9.
    Harris JR, Lippman ME, Veronesi U, Willett W (1992) Breast cancer, part 2. N Engl J Med 327:390–398Google Scholar
  10. 10.
    Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O, Mellemgaard A, Soini I, Tulinius H (1990) Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer 46:597–603Google Scholar
  11. 11.
    Kalache A, Maguire A, Thompson SG (1993) Age at last full-term pregnancy and risk of breast cancer. Lancet 341:33–36Google Scholar
  12. 12.
    Talamini R, Franceschi S, La Vecchia C, Negri E, Borsa L, Montellu M, Falcini F, Conti E, Rossi C (1996) The role of reproductive and menstrual factors in cancer of the breast before and after menopause. Eur J Cancer 32A:303–310Google Scholar
  13. 13.
    Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331:5–9Google Scholar
  14. 14.
    Kroman N, Wohlfahrt J, Andersen KW, Mouriudsen HT, Westergaard T, Melbye M (1997) Time since childbirth and prognosis in primary breast cancer: population based study. Br Med J 315:851–855Google Scholar
  15. 15.
    Meduri G, Charnaux N, Spyratos F, Hacene K, Loosfelt H, Milgrom E (2003) Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas. Cancer 97:1810–1816Google Scholar
  16. 16.
    Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Burke B, Sutcliffe SB, Koren G (1992) Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 166:781–787Google Scholar
  17. 17.
    Rookus MA, van Leeuwen FE (1996) Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study. J Natl Cancer Inst 88:1759–1764Google Scholar
  18. 18.
    Melbye M, Wohlfahrt J, Olsen JH, Frisch M, Westergaard T, Helweg-Larsen K, Andersen PK (1997) Induced abortion and the risk of breast cancer. N Engl J Med 336:81–85Google Scholar
  19. 19.
    Musey VC, Collins DC, Brogan DR, Santos VR, Musey PI, Martino-Saltzman D, Preedy JRK (1987) Long term effects of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab 64:111–118Google Scholar
  20. 20.
    Musey VC, Collins DC, Musey PI, Martino-Saltzman D, Preedy JRK (1987) Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 316:229–234Google Scholar
  21. 21.
    Newcomb P, Egan KM, Titus-Ernstoff L, Trentham-Dietz A, Greenberg ER, Baron JA, Willett WC, Stampfer MJ (1999) Lactation in relation to postmenopausal breast cancer. Am J Epidemiol 150:174–182Google Scholar
  22. 22.
    Kvale G, Heuch I (1987) Lactation and cancer risk: is there a relation specific to breast cancer? J Epidemiol Community Health 42:30–37Google Scholar
  23. 23.
    London SJ, Colditz GA, Stampfer MJ, Willett WC, Rosner BA, Corsano K, Speizer FE (1990) Lactation and risk of breast cancer in a cohort of US women. Am J Epidemiol 132:17–26Google Scholar
  24. 24.
    Beral V, Bull D, Peto R, Reeves G (Collaborative Group on Hormonal Factors in Breast Cancer) (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without disease. Lancet 360:187–195Google Scholar
  25. 25.
    Bernier MO, Plu-Bureau G, Bossard N, Ayzac L, Thalabard JC (2000) Breastfeeding and risk of breast cancer: a meta-analysis of published studies. Hum Reprod Update 6:374–386Google Scholar
  26. 26.
    Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339–2347Google Scholar
  27. 27.
    Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (Breast Cancer Linkage Consortium) (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695Google Scholar
  28. 28.
    Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15:103–105Google Scholar
  29. 29.
    Gayther SA, Ponder BA (1997) Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Mol Med Today 3:168–174Google Scholar
  30. 30.
    Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Cough FJ, Jenkins RB (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633–1637Google Scholar
  31. 31.
    Narod SA, Risch H, Mosichi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BAJ (The Hereditary Ovarian Cancer Clinical Study Group) (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339:424–428Google Scholar
  32. 32.
    Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baroch G, Fishman A, Menczer J, Ebbers SM, Tucker MA, Wacholder S, Struewing JP, Friedman E, Piura B (National Israel Ovarian Cancer Study Group) (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235–240Google Scholar
  33. 33.
    Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773–1779Google Scholar
  34. 34.
    Bulbrook RD (1972) Urinary androgen excretion and the etiology of breast cancer. J Natl Cancer Inst 48:1039–1042Google Scholar
  35. 35.
    Wang DY, Allen DS, De Stavola BL, Fentiman IS, Brussen J, Bulbrook RD, Thomas BS, Hayward JL, Reed MJ (2000) Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey. Br J Cancer 82:1577–1584Google Scholar
  36. 36.
    Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17–35Google Scholar
  37. 37.
    Speroff L, Fritz MA (2005) The breast. In: Speroff L, Fritz MA (eds) Clinical endocrinology and infertility. Lippincott, Williams & Wilkins, Philadelphia, pp 573–620Google Scholar
  38. 38.
    Dickinson LE, MacMahon B, Cole P, Brown JB (1974) Estrogen profiles of Oriental and Caucasian women in Hawaii. N Engl J Med 291:1211–1213Google Scholar
  39. 39.
    Russo J, Russo ICH (1994) Towards a physiological approach to breast cancer prevention. Can Epid Biom Prev 3:353–364Google Scholar
  40. 40.
    Yong LC, Brown CC, Schatzkin A, Schairer C (1996) Prospective study of relative weight and risk of breast cancer: the Breast Cancer Detection Demonstration Project follow-up study 1979 to 1987–1989. Am J Epidemiol 143:985–995Google Scholar
  41. 41.
    Schapira DV, Clark RA, Wolff PA, Jarrett AR, Kumar NB, Aziz NM (1994) Visceral obesity and breast cancer risk. Cancer 74:632–639Google Scholar
  42. 42.
    Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276–285Google Scholar
  43. 43.
    Perel E, Wilkins D, Dillinger DW (1980) The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem 13:89–94Google Scholar
  44. 44.
    Dao TL, Hayes C, Libby PR (1974) Steroid sulfatase activities in human breast tumors. Proc Soc Exp Biol Med 146:381–384Google Scholar
  45. 45.
    Pollow K, Boquoi E, Baumann J, Schmidt-Gollwitzer M, Pollow B (1977) Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue. Molec Cell Endocr 6:333–348Google Scholar
  46. 46.
    Miller WR, O’Neill JS (1989) The relevance of local oestrogen metabolism within the breast. Proc R Soc Edinb 95B:203–217Google Scholar
  47. 47.
    Blankenstein MA, Maitimu-Smeele I, Donker GH, Daorszweski J, Milewicz A, Thijssen JH (1994) On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 41:891–896Google Scholar
  48. 48.
    Santner SJ, Feil PD, Santen RJ (1984) In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocr Metab 59:29–33Google Scholar
  49. 49.
    Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer. J Clin Endocr Metab 81:1460–1464Google Scholar
  50. 50.
    Sigelmann-Danieli N, Buetow KH (1999) Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 79:456–463Google Scholar
  51. 51.
    Harada N, Utsumi T, Takagi Y (1993) Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons I and promoters, and switching of tissue-specific exons I in carcinogenesis. Proc Natl Acad Sci USA 90:11312–11316Google Scholar
  52. 52.
    Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S (1996) Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 59:163–171Google Scholar
  53. 53.
    Khan SA, Rogers MA, Obando JA, Tamsen A (1994) Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54:993–997Google Scholar
  54. 54.
    Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:1811–1815Google Scholar
  55. 55.
    Hall JM, McDonnell DP (1999) The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and anti-estrogens. Endocrinology 140:5566–5578Google Scholar
  56. 56.
    Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN, Atkin SL (1999) Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res 59:525–528Google Scholar
  57. 57.
    Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson JA, Coombes RC (2004) The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10:2421–2428Google Scholar
  58. 58.
    Bolton JL, Pisha E, Zhang F, Qiu S (1998) Role of quinoids in estrogen carcinogenesis. Chem Res Toxicol 11:1113–1127Google Scholar
  59. 59.
    Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57:5493–5497Google Scholar
  60. 60.
    Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59:4870–4885Google Scholar
  61. 61.
    Chang KJ, Lee TTY, Linarez-Cruz G, Fournier S, de Lignières B (1995) Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 63:785–791Google Scholar
  62. 62.
    Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E (1995) The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 136:164–171Google Scholar
  63. 63.
    Foidart JM, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, de Lignières B (1998) Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 69:963–969Google Scholar
  64. 64.
    Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P (1986) Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 63:1174–1180Google Scholar
  65. 65.
    Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW (1994) A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 18:79–85Google Scholar
  66. 66.
    Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S (2001) Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285:171–176Google Scholar
  67. 67.
    Colacurci N, Fornaro F, De Franciscis P, Mele D, Palermo M, del Vecchio W (2001) Effects of a short-term suspension of hormone replacement therapy on mammographic density. Fertil Steril 76:451–455Google Scholar
  68. 68.
    McGuire WL, Clark GM (1992) Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756–1761Google Scholar
  69. 69.
    Early Breast Cancer Trialists’ Collaborative Group (2001) Tamoxifen for early breast cancer. The Cochrane Database of Systematic Reviews, issue 1, article no CD000486Google Scholar
  70. 70.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628–4635Google Scholar
  71. 71.
    Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W (Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group) (2003) Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711–1717Google Scholar
  72. 72.
    Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol 20:4621–4627Google Scholar
  73. 73.
    Davidson NE, O’Neill A, Vukov A, Osborne CK, Martino S, White D, Abeloff M (2003) Chemohormonal therapy in premenopausal node-positive, receptorpositive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 22:5 (Abstract 15)Google Scholar
  74. 74.
    Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3817–3827Google Scholar
  75. 75.
    Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690Google Scholar
  76. 76.
    Helgason S, Wilking N, Carlstrom K, Damber MG, von Schoultz B (1982) A comparative study of the estrogenic effects of tamoxifen and 17 beta-estradiol in postmenopausal women. J Clin Endocrinol Metab 54:404–408Google Scholar
  77. 77.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388CrossRefPubMedGoogle Scholar
  78. 78.
    Wertheimer MD, Costanza ME, Dodson TF, D’Orsi C, Pastides H, Zapka JG (1986) Increasing the effort toward breast cancer detection. JAMA 255:1311–1315CrossRefPubMedGoogle Scholar
  79. 79.
    Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300CrossRefPubMedGoogle Scholar
  80. 80.
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134CrossRefPubMedGoogle Scholar
  81. 81.
    Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T (ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group) (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139CrossRefPubMedGoogle Scholar
  82. 82.
    Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101–2109CrossRefPubMedGoogle Scholar
  83. 83.
    Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431–2442CrossRefPubMedGoogle Scholar
  84. 84.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2001) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802CrossRefGoogle Scholar
  85. 85.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (Intergroup Exemestane Study) (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092CrossRefPubMedGoogle Scholar
  86. 86.
    Lynn J (2004) Fulvestrant (‘Faslodex’)—a new hormonal treatment for advanced breast cancer. Eur J Oncol Nurs 8(Suppl 2):S83–S88CrossRefPubMedGoogle Scholar
  87. 87.
    Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women—a prospective combined analysis of two multicenter trials. Cancer 98:229–238CrossRefPubMedGoogle Scholar
  88. 88.
    Carlson RW, Henderson IC (2003) Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 80(Suppl 1):S19–S26CrossRefPubMedGoogle Scholar
  89. 89.
    Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, Ameye L, Weltens C, Christiaens MR, Vergote I, Paridaens R (2005) Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 16:70–74CrossRefPubMedGoogle Scholar
  90. 90.
    Dixon JM, Anderson TJ, Miller WR (2002) Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 38:2214–2221CrossRefPubMedGoogle Scholar

Copyright information

© European Board and College of Obstetrics and Gynaecology 2005

Authors and Affiliations

  1. 1.Department of Obstetrics & GynaecologyUniversity of MuensterMuensterGermany
  2. 2.Department of GynaecologyUniversity of MarburgMarburgGermany

Personalised recommendations